Tioga Pharmaceuticals Receives $10,000,000 Series B Funding

  • Feed Type
  • Date
  • Company Name
    Tioga Pharmaceuticals
  • Mailing Address
    9393 Towne Centre Dr. San Diego, CA 92121
  • Company Description
    Tioga Pharmaceuticals is engaged in the development of novel therapies for the treatment of gastrointestinal diseases. Tioga is developing asimadoline, a proprietary small molecule, for treating irritable bowel syndrome (IBS) and post operative ileus.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Tioga is currently conducting a Phase 3 trial of its compound, asimadoline, for the treatment of diarrhea-predominant irritable bowel syndrome (D-IBS) under a special protocol assessment with the U.S. Food and Drug Administration (FDA).
  • M&A Terms
  • Venture Investor
    Thomas, McNerny & Partners
  • Venture Investor
    Genesys Capital

Trending on Xconomy